DE69330638T2 - Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine zur herstrllung eines medikaments zur behandlung von bestimmten schmerzen und ödem - Google Patents

Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine zur herstrllung eines medikaments zur behandlung von bestimmten schmerzen und ödem

Info

Publication number
DE69330638T2
DE69330638T2 DE69330638T DE69330638T DE69330638T2 DE 69330638 T2 DE69330638 T2 DE 69330638T2 DE 69330638 T DE69330638 T DE 69330638T DE 69330638 T DE69330638 T DE 69330638T DE 69330638 T2 DE69330638 T2 DE 69330638T2
Authority
DE
Germany
Prior art keywords
dichlorophenyl
diamino
triazine
edm
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69330638T
Other languages
English (en)
Other versions
DE69330638D1 (de
Inventor
Meire Nakamura-Craig
Michael John Leach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of DE69330638D1 publication Critical patent/DE69330638D1/de
Publication of DE69330638T2 publication Critical patent/DE69330638T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
DE69330638T 1992-02-19 1993-02-18 Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine zur herstrllung eines medikaments zur behandlung von bestimmten schmerzen und ödem Expired - Fee Related DE69330638T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929203483A GB9203483D0 (en) 1992-02-19 1992-02-19 Anti-inflammatory compounds
PCT/GB1993/000341 WO1993016700A1 (en) 1992-02-19 1993-02-18 Use of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine for the treatment of pain and ×dema

Publications (2)

Publication Number Publication Date
DE69330638D1 DE69330638D1 (de) 2001-09-27
DE69330638T2 true DE69330638T2 (de) 2002-06-27

Family

ID=10710643

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69330638T Expired - Fee Related DE69330638T2 (de) 1992-02-19 1993-02-18 Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine zur herstrllung eines medikaments zur behandlung von bestimmten schmerzen und ödem

Country Status (18)

Country Link
US (1) US5712277A (de)
EP (1) EP0626851B1 (de)
KR (1) KR950700067A (de)
AT (1) ATE204476T1 (de)
AU (1) AU684711B2 (de)
CA (1) CA2129043C (de)
CY (1) CY2299B1 (de)
DE (1) DE69330638T2 (de)
DK (1) DK0626851T3 (de)
ES (1) ES2162813T3 (de)
GB (2) GB9203483D0 (de)
GR (1) GR3036958T3 (de)
IL (1) IL104775A (de)
MX (1) MX9300927A (de)
NZ (1) NZ249197A (de)
PT (1) PT626851E (de)
TW (1) TW226331B (de)
WO (1) WO1993016700A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9424766D0 (en) * 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
WO1996020934A1 (en) * 1994-12-30 1996-07-11 The Wellcome Foundation Limited Process for the preparation of lamotrigine
GB9625795D0 (en) * 1996-12-12 1997-01-29 Smithkline Beecham Plc Novel treatment
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
EP1169060B1 (de) * 1999-04-09 2005-08-31 Euro-Celtique S.A. Natrium kanalblocker zusammensetzungen und deren verwendung
EP1423168B1 (de) * 2001-09-03 2006-02-08 Newron Pharmaceuticals S.p.A. Pharmazeutische zusammensetzung mit gabapentin oder deren analog und einem alpha-aminoamid und analgetische verwendung dieser zusammensetzung
AU2005282028B2 (en) * 2004-09-10 2011-03-24 Newron Pharmaceuticals S.P.A. (halobenzyloxy) benzylamino-propanamides as sodium and/or calcium channel selective modulators
CN107921046B (zh) * 2015-06-12 2022-10-14 格林威治大学 作为干扰素-γ抑制剂的三嗪衍生物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3637688A (en) * 1970-01-09 1972-01-25 American Home Prod 6-(fluoro and trifluoromethyl phenyl)-3 5-diamino - 1 2 4 - triazines and substituted - 6 - phenylalkyl-3,5-diamino-1 2 4-triazines
US4310551A (en) * 1979-03-19 1982-01-12 Diamond Shamrock Corporation Pharmacologically active substituted 1,2,4-triazines
DK153787C (da) * 1979-06-01 1989-01-16 Wellcome Found Analogifremgangsmaade til fremstilling af substituerede 3,5-diamino-6-phenyl-1,2,4-triaziner og alfa-cyanobenzyliden-aminoguanidinforbindelser til anvendelse som mellemprodukter herved
GB8613183D0 (en) * 1986-05-30 1986-07-02 Wellcome Found Triazine salt
GB9012312D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds

Also Published As

Publication number Publication date
GR3036958T3 (en) 2002-01-31
GB2277265A (en) 1994-10-26
AU3509293A (en) 1993-09-13
MX9300927A (es) 1994-08-31
CA2129043A1 (en) 1993-09-02
US5712277A (en) 1998-01-27
GB9203483D0 (en) 1992-04-08
EP0626851B1 (de) 2001-08-22
DK0626851T3 (da) 2001-12-03
CA2129043C (en) 2004-01-27
JPH07503968A (ja) 1995-04-27
AU684711B2 (en) 1998-01-08
EP0626851A1 (de) 1994-12-07
IL104775A0 (en) 1993-06-10
PT626851E (pt) 2002-02-28
IL104775A (en) 1997-02-18
CY2299B1 (en) 2003-07-04
WO1993016700A1 (en) 1993-09-02
GB9414348D0 (en) 1994-09-07
JP3713271B2 (ja) 2005-11-09
KR950700067A (ko) 1995-01-16
DE69330638D1 (de) 2001-09-27
ATE204476T1 (de) 2001-09-15
ES2162813T3 (es) 2002-01-16
NZ249197A (en) 1997-05-26
TW226331B (de) 1994-07-11
GB2277265B (en) 1996-01-10

Similar Documents

Publication Publication Date Title
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
GEP20002300B (en) Purified Forms of Dnase, Method for Its Production, Pharmaceutical Composition and Use Thereof
DE69012261T2 (de) Verwendung von Sertralin zur Behandlung verfrühter Ejakulation.
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
DE68923151D1 (de) Verwendung von Trifluormethylphenyl-Tetrahydropyridinen zur Herstellung von Arzneimitteln zur Behandlung anxio-depressiver Erkrankungen.
DE69521536T2 (de) Zusammensetzungen die G-CSF und ein TNF-Bindungsprotein enthalten
DE69330638T2 (de) Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine zur herstrllung eines medikaments zur behandlung von bestimmten schmerzen und ödem
DE69304843D1 (de) Methode zur Behandlung von Haarausfall
ES2157961T3 (es) Inhibicion del hirsutismo y la alopecia en mujeres.
DE69307702T2 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
DE69424415T2 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
ATE254919T1 (de) Verwendung von penciclovir zur behandlung von menschlichem herpes virus-8
DE59504374D1 (de) Verwendung von Deoxyspergualin zur Herstellung eines Arzneimittels zur Behandlung von entzündlich-hyperreaktiven Erkrankungen
ATE136463T1 (de) Verwendung von 1,2,3,4-tetrahydroacridinen zur behandlung von aids, sowie verbindungen
DE69429538D1 (de) Verwendung von 2-aminopurinderivaten zur behandlung und prophylaxe der menschlichen herpesvirus 6 infektionen
DE69218544D1 (de) Verwendung von BMY 14802 zur Behandlung von Angstzuständen bei Patienten mit Benzodiazepin-Entzugserscheinungen
ATE147980T1 (de) Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4,-triaz nisethionat zur behandlung und vorbeugung von drogenabhaengigkeit,-toleranz und- sensibilisierung
MX9701528A (es) Derivados de 1, 1, 2,- trifenilbut-1-eno para tratar la enfermedad de alzheimer.
MX9706404A (es) Metodo para tratar deplecion de adenosina.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee